Italia markets closed

Dow Jones
39.806,77
-196,82(-0,49%)
Nasdaq
16.794,88
+108,91(+0,65%)
Nikkei 225
39.069,68
+282,30(+0,73%)
EUR/USD
1,0860
-0,0012(-0,11%)
Bitcoin EUR
63.531,15
+2.551,60(+4,18%)
CMC Crypto 200
1.467,01
+112,60(+8,31%)

NVCR Dec 2024 25.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

5,45

+1,45

(+36,25%)

In data: 12:46PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in